ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Etoricoxib

Also written as “etoricoxib”, “MK0663, etoricoxib” and “MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days”.

Its studies are mostly in Osteoarthritis · Pain · Low Back Pain · Acute Pain · Dysmenorrhea, led by 7 companies.

Drug pageEtoricoxib: every studyMany companies study it; this page follows only the 34 they lead. All 71 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 25, 200434 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Organon230 open or runningphase 4since Aug 25, 2004Aug 25, 2004none ahead
Laboratorios Silanes S.A. de C.V.its history only61 open or runningphase 3since Jul 13, 2021Jul 13, 2021Dec 31, 2026phase 3 · NCT06863701
Analgesic Solutionsits history only10 open or runningphase 4since Dec 20, 2010Dec 20, 2010none ahead
Dexa Medica Groupits history only10 open or runningno phasesince Jan 30, 2018Jan 30, 2018none ahead
Laboratorios Liomontits history only10 open or runningphase 3since Apr 15, 2026Apr 15, 2026none ahead
Pharmtechnologyits history only10 open or runningphase 1since Mar 31, 2021Mar 31, 2021none ahead
X-pert Medits history only10 open or runningphase 1since Jan 5, 2011Jan 5, 2011none ahead

Also a collaborator on its studies: EPIC Research CRO, PT Equilab International and Merck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Organon only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 6 studies since Aug 25, 2004.

  1. Oct 18, 2005Phase 2 study in OsteoarthritisNCT00242489 · 1,167 enrolled
  2. Dec 9, 2005Phase 2 study in Arthritis, RheumatoidNCT00264147 · 761 enrolled
  3. Dec 21, 2005Phase 3 study in OsteoarthritisNCT00269191 · 528 enrolled
  4. Sep 22, 20062 phase 4 studies in PainNCT00380627, NCT00380523
  5. Oct 26, 20062 phase 3 studies in Low Back PainNCT00393354, NCT00393211
  6. Jun 6, 2008Phase 3 study in Postoperative Dental PainNCT00694369 · 588 enrolled
  7. Sep 22, 2008Phase 4 study in PainNCT00757627 · 500 enrolled
  8. Nov 5, 2008Phase 3 study in Acute Pain Following a Total Abdominal HysterectomyNCT00788710 · 430 enrolled
  9. Jan 7, 2009Phase 3 study in Pain, PostoperativeNCT00820027 · 776 enrolled
  10. Sep 22, 20102 phase 3 studiesNCT01208207, NCT01208181
  11. Sep 2, 2011Phase 4 study in OsteoarthritisNCT01429168
  12. Oct 27, 2011Phase 3 study in DysmenorrheaNCT01462370 · 139 enrolled
  13. Mar 12, 2012Phase 3 study in Osteoarthritis, KneeNCT01554163 · 239 enrolled
  14. Nov 5, 2013Phase 2 study in Osteoarthritis PainNCT01980940 · 70 enrolled

TargetBeta

PTGS2 →read by rule
“Cyclooxygenase-2 inhibitor”ChEMBL 37, by rule

Other programs on PTGS2

ProgramCompanyFurthest phaseStudies
AcetaminophenruleJohnson & Johnsonphase 4136
IbuprofenrulePfizerphase 4113
AspirinruleBayerphase 484
CelecoxibruleViatrisphase 478
MeloxicamruleBoehringer Ingelheimphase 467
dexketoprofenruleMenarini Groupphase 48
SulfasalazineruleBristol-Myers Squibbphase 47
dexibuprofenruleaponia-laboratories-incphase 46
BenzydamineruleAngelini Pharmaphase 44
DipyroneruleHypera Pharmaphase 44
PiroxicamruleTaisho Pharmaceuticalphase 44
FlurbiprofenruleGlaxoSmithKlinephase 312

Studies

All 23 Organon leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01980940Osteoarthritis Pain2CompletedNov 26, 201470
NCT01554163Osteoarthritis, Knee3CompletedMar 2013239
NCT01462370Dysmenorrhea3CompletedJun 2012139
NCT01429168Osteoarthritis4WithdrawnAug 20120
NCT01208207Spondylitis, Ankylosing3CompletedNov 12, 20141,015
NCT01208181Arthritis, Rheumatoid3CompletedJun 9, 20141,404
NCT00820027Pain, Postoperative3CompletedDec 13, 2010776
NCT00788710Acute Pain Following a Total Abdominal Hysterectomy3CompletedJul 2010430
NCT00757627Pain4CompletedDec 2008500
NCT00694369Postoperative Dental Pain3CompletedDec 2008588
NCT00393354Low Back Pain3CompletedNov 2000325
NCT00393211Low Back Pain3CompletedNov 2000319
NCT00380627Pain4CompletedJan 31, 2006337
NCT00380523Pain4CompletedMay 2005237
NCT00269191Osteoarthritis3CompletedNov 7, 2003528
NCT00264147Arthritis, Rheumatoid2CompletedMar 2008761
NCT00242489Osteoarthritis2CompletedFeb 19991,167
NCT00095017Bone Neoplasms2Withdrawn0
NCT00092781Osteoarthritis3CompletedFeb 1, 2005500
NCT00092768Osteoarthritis3CompletedFeb 1, 2005500
NCT00092755Osteoarthritis3CompletedNov 13, 2003548
NCT00092729Dysmenorrhea3CompletedDec 6, 2002129
NCT00090181Chronic Low Back Pain4CompletedMar 2005401

How it is read

Names in the registry

  • “etoricoxib”, 7 entries
  • “Etoricoxib”, 4 entries
  • “MK0663, etoricoxib”, 3 entries
  • “MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days”, 2 entries
  • “Etoricoxib 90 mg”, 2 entries

Codes read as this program: MK0663.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.